Advanced epithelial ovarian cancer, cancer of the fallopian tube and primary peritoneal cancer have a poor prognosis and a high rate of disease recurrence following primary therapy. Recurrent ...

While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

The therapeutic landscape in recurrent ovarian cancer is characterized by well-established strategies, a number of concepts still lacking confirmation in prospective randomized trials and numerous ...